Benznidazole levels in blood vary with age in rats by Bulffer, Romina Fernanda et al.
374
online | memorias.ioc.fiocruz.br
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(3): 374-377, May 2011
Chagas disease is endemic in Central and South 
America. Approximately 16-18 million people are in-
fected with Trypanosoma cruzi and 100 million are at 
risk of infection (Pinto Dias et al. 2002, Coura & Castro 
2002, Teixeira et al. 2006, Jannin & Villa 2007, Rassi 
Jr et al. 2009). Two drugs are available for the etiologi-
cal treatment of Chagas disease: a nitrofurane [nifurti-
mox (Nfx)] and a nitroimidazole [benznidazole (Bz)] 
(Tanowitz et al. 1992, Rodriguez-Morales 2005, Jannin 
& Villa 2007). Currently, Bz is used in Argentina, Brazil 
and Uruguay to treat the acute or indeterminate chronic 
phases of Chagas disease (Pinto Dias et al. 2002, Jan-
nin & Villa 2007, Sosa-Estani et al. 2009, Boiani et al. 
2010). These drugs are widely accepted for treatment of 
the acute phase of the disease (OPS/OMS 1998, Coura & 
Castro 2002, Rodriguez Morales 2005, Jannin & Villa 
2007). However, their use in the treatment of the chronic 
phases of the disease remains controversial (Rodriguez 
Morales 2005, Jannin & Villa 2007, Castro et al. 2008). 
Most acutely infected patients are children with a mean 
age of four years. Congenital transmission to newborns 
contributes to the young average age of patients, in ad-
dition to the triatomine vectors. The congenital route 
of infection might be relevant to endemic areas as well 
as non-endemic areas in future years as infected indi-
viduals migrate later in life. Public health policies have 
been implemented in endemic areas, with the aims of 
identifying pregnant women positive for T. cruzi as well 
as promptly treating infected children immediately af-
ter parasitological and serological confirmation (Pinto 
Dias et al. 2002, Coura & Castro 2002, Sosa Estani et al. 
2009). It is important to emphasise that both the duration 
of Bz chemotherapeutic effects as well as its toxicity are 
fundamentally controlled by its reductive metabolism in 
many organs and the faeces. The available information 
on Bz metabolic transformations and the mechanism of 
toxicity was exhaustively detailed in previous reviews 
(Castro & de Toranzo 1988, Castro 2000, Castro et al. 
2006). A major part of Bz metabolism in the rat body 
occurs in the liver microsomal fraction (Masana et al. 
1984). Enzymatic activity is present at very low levels in 
newborn rats and higher levels in 28-day-old rats (Agui-
lar et al. 1987). These findings spurred us to investigate 
the blood levels of Bz at different times after intragastric 
administration, which might vary after administration 
based upon the age of the patient. To begin, we needed a 
validated high-pressure liquid chromatography with UV 
detector (HP�C-UV) methodology for the determina-
tion of Bz levels in whole blood. Outbred male Sprague 
Dawley rats 14, 21 and 70-days-old weighing 29-32 g, 
43-46 g and 260-290 g, respectively, were used (5 ani-
mals per group). Animals were kept in a controlled room 
with a 12 h light: 12 h dark cycle (light phase from 6-18 
h), temperature of 23 ± 2ºC and relative humidity of 45-
65%. The procedures used for breeding, housing and 
handling animals were those described by the National 
Food, Drug and Medical Technology Administration 
(Buenos Aires). Animals had free access to food and 
water. N-benzyl-2-nitro-1-imidazole acetamide (Bz, 
98.6% pure) was a gift from Roche. Animals were given 
a single Bz dose of 100 mg/kg bw as a homogeneous 
suspension in 1% carboxymethylcellulose (CMC), while 
control rats received only 1% CMC. Animals were eu-
thanized by decapitation at different times (1, 3, 6 and 
24 h) post-treatment, and blood samples were taken in 
heparinised tubes and processed. One millilitre of blood 
sample was diluted with 1.5 m� of saline solution. The 
samples were extracted with dichloromethane (15 m�) 
in an Extrelut® column (prepared in 10 m� syringe 
with 2.4 g of Extrelut®, Merck Chemical). Solvent was 
evaporated to dryness under a nitrogen atmosphere. 
Samples were resuspended in 0.5 m� of mobile phase 
(CH3OH:H2O, 60:40), filtered with nylon filters (pore 
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Benznidazole (Bz) exhibits toxic side effects in animal studies and clinical use. Reductive metabolism of Bz in 
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size 0.22 µm) and analysed (50 µ�) by HP�C using a 
Waters system with a C18 ODS Hypersil column (20 cm 
x 2.1 mm ID, 5 µm particle size) and a diode array detec-
tor (DAD). The mobile phase, consisting of CH3OH:H2O 
(60:40), was delivered isocratically at a flow rate of 0.2 
m�/min. Column effluent was monitored at 320 nm 
(maximum absorbance of Bz). Bz was quantified by the 
peak-area ratio compared to a standard calibration curve 
which was made with identically-treated standards rang-
ing from 0.5-100 μg/mL. A standard solution of Bz (100 
µg/m�) in CH3OH:H2O (60:40) was prepared from a 
stock solution of Bz (1 mg/m� of dimethylformamide) 
and stored in glass vials at -20ºC (it was stable more than 
one month). USP 30-NF 25, ICH Q2B and FDA Bioana-
lytical guidelines were used for validation of the method. 
The main parameters assayed were: accuracy, precision, 
specificity, linearity, detection limit and robustness. 
Accuracy - Blood samples were spiked with known 
Bz concentrations (1.5, 5, 15, 30 and 75 µg/m�). After 
extraction of the analyte from the matrix and injection 
into the HP�C system, its recovery was determined by 
comparing the response of the extract with the response 
of the standard (identical spiked Bz concentration in 
physiologic solution). The recovery efficiency of Bz add-
ed to blood was 94%. The detection limit was 0.25 µg/
m�, based on the signal to noise approach (ratio of 3:1). 
Precision - The precision of the Bz assay was deter-
mined by repeatability (intraday) and intermediate pre-
cision or reproducibility (interday) in samples contain-
ing 10 µg/m� of Bz. The results were expressed as the 
relative standard deviation of a series of measurements. 
Repeatability - Obtained by examining 10 dupli-
cated, separated samples and analysing each one three 
times by HP�C. 
Reproducibility - Determined through the use of differ-
ent analysts on successive days. We used three samples for 
triplicate and analysed each one three times by HP�C.
Specificity - Not applicable. The absence of matrix in-
terferences for the quantitative method was demonstrated 
by the analysis of five control animals in each assay. 
Robustness - In this test, we examined the capacity 
of the assay to be affected by small but deliberate varia-
tions in procedural parameters such as temperature (25ºC 
and -20ºC) and light conditions (light or darkness). The 
significance of differences between mean values was as-
sessed by the unpaired t test (Student t test) (Gad 2001). 
Calculations were performed using GraphPad Software. 
Differences were considered significant when p < 0.05. 
A characteristic chromatogram of a blood sample from 
an animal treated with Bz showed a mean retention time 
of 3.7 ± 0.2 min, with an overall chromatographic run 
time of 6 min. There were no chromatographic interfer-
ences; the biological matrix didn’t interfere with drug 
determination. The peak area of Bz vs. its concentration 
displayed a linear relationship over the tested range of 
0.5-100 µg/m� (y = 370253x - 44530). The linear regres-
sion analysis indicated no significant deviation from lin-
earity (r2: 0.9995). Replicate analysis of blood samples 
containing Bz gave an intra-day coefficient of variation 
of 4.35% (Table I). Analysis of the samples on differ-
ent days yielded an interday coefficient of variation less 
than 5% (Table I). The robustness assay showed that 
the method is robust for small variations in parameters 
such as temperature (25ºC and -20ºC) and light condi-
tions (light or darkness) (Table I). The initial part of our 
work was the development and validation of an accessi-
ble HP�C-UV methodology for the determination of Bz 
levels in rat whole blood. The procedure, in our hands, 
have to be accurate, reproducible, repetitive and robust 
(Table I). The procedure might be applicable to human-
derived samples. That possibility remains to be inves-
tigated, considering that other drugs or xenobiotics re-
sulting from additional treatments or exposures may be 
simultaneously present in human-derived samples. The 
above methodology was used to determine whole blood 
levels at times ranging from 1-24 h in 14, 21 and 70-day-
old rats that received a single dose of 100 mg/kg of the 
drug. At 14-days-old, rats have 61% of the liver micro-
somal capacity to metabolise Bz compared to the adult 
rat and at 21-28-days-old, the level of Bz-nitroreductase 
activity attains the level of that of an adult animal (Agui-
lar et al. 1987). Accordingly, whole blood levels of Bz 
at 1, 3, 6 and 24 h after administration in the 14-day-
old animals are significantly higher and last longer than 
in those of 21 or 70-day-old rats (Table II). These re-
TAB�E I
Validation parameters of benznidazole (Bz) high-pressure 
liquid chromatography with UV detector (HP�C-UV) 
assay in rat blood samples
Bz (µg/m�)
Mean ± SD RSD
Accuracy (n = 9) 8.14 ± 0.34 4.18
Precision
   Repetitivity (n = 20)
   Reproducibility
      Analyst I, day 1 (n = 9)
      Analyst I, day 2 (n =9 )









Robustness (n = 9)
   25ºC light
   25ºC darkness







a: 25ºC light vs. 25ºC darkness: p > 0.05; b: 25ºC light vs. 
-20ºC: p > 0.05. RSD: relative standard deviation. Repeatabil-
ity was obtained examining 10 duplicated separated samples 
analysed three times each one by HP�C system. Reproducibil-
ity was determinate with different analysts in successive days. 
We used three samples for triplicate and analysed three times 
each one by HP�C system. Analyst I, day 1 vs. analyst I, day 
2: p > 0.05. Analyst I, day 1 vs. analyst II, day 1: p > 0.05. In 
robustness, values represent means ± SD from nine independ-
ent samples analysed three times by HP�C. 
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sults underscore the relevance of liver microsomal Bz 
nitroreductase enzymes in controlling blood levels of 
this nitroheterocyclic drug. Those enzymes’ activities 
are particularly low in newborn animals (e.g. 1-7-day-
old rats) (Aguilar et al. 1987). P450 reductase and P450 
enzymes, to a smaller extent, mediate nitroreduction of 
Bz in rat liver microsomes (Masana et al. 1984). Both 
enzymes have long been known to be deficient perina-
tally in liver microsomes from most species of labora-
tory animals, as well as from humans P450 and P450 
reductase mixed-function oxygenase activity in human 
livers is particularly low in newborns and remains lower 
than activity in adults during the first four years of life. 
An additional source of relevant anaerobic metabolic 
degradation of Bz is present in human faeces (Toranzo 
et al. 1983). Newborns lack bacterial faecal ability to bi-
otransform xenobiotics (Scheline 1973). This study and 
past results (Aguilar et al. 1987) provide a rationale for 
the observation that Bz treatment of young children is 
accompanied with fewer undesirable side effects than 
treatment of adults (Pinto Dias 2000, 2003). Bz nitrore-
ductive metabolism controls pharmacokinetic proper-
ties, the deleterious effects on different tissues (Castro et 
al. 2006) and antiparasitic effects (Docampo & Moreno 
1986) due to the generation of reactive intermediates 
during the reductive process that covalently bind to the 
nuclear and kinetoplastic DNA, proteins and lipids of T. 
cruzi (de Toranzo et al. 1988). The activities of the drug 
metabolising enzymes governing these processes are in-
fluenced by multiple factors, including not only age, but 
also P450 enzyme polymorphisms, hormone status (sex, 
adrenal, thyroid and insulin), nutritional status (deficien-
cies and diet), disease and exposure to xenobiotics (drugs, 
occupational and environmental factors of inhibitory or 
inductive effects) (Gram & Gilette 1971, Ingelman-Sun-
dberg 2004, Wauthier et al. 2007). Any or all factors may 
contribute to the variation in the adverse effects of Bz on 
patients (Castro & de Toranzo 1988, Castro et al. 2006). 
The efficacy of chemotherapeutic effects of Bz on T. 
cruzi is not only due to available blood levels of Bz or to 
the metabolic production of reactive metabolites in the 
parasite itself. Chemotherapeutic activity of Bz against 
different T. cruzi strains is most likely due to differences 
in drug susceptibility arising from the above-mentioned 
Bz metabolic activation processes. This variation could 
account for some contradictory observations concerning 
the efficiency of Bz treatment in children when studies 
were performed in different geographic areas. However, 
Bz pharmacokinetics are more likely to be affected by 
the differences observed regarding parasitological cure 
rates between acute and indeterminate (< 15 years old) 
forms and the later chronic stage [reviewed by Urbina 
(2009) and Cançado (2002)].
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